Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign
- 1 December 2020
- journal article
- letter
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 83 (6) , e453-e454
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Androgenetic alopecia in COVID-19: Compared to what?Journal of the American Academy of Dermatology, 2020
- Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”Journal of the American Academy of Dermatology, 2020
- Androgen sensitivity gateway to COVID‐19 disease severityDrug Development Research, 2020
- Androgenetic alopecia in men aged 40-69 years: prevalence and risk factorsBritish Journal of Dermatology, 2003
- Male Pattern Baldness: classification and IncidenceSouthern Medical Journal, 1975